Prescription medicine
Toripalimab Brand names: Loqtorzi
Toripalimab (Loqtorzi) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the toripalimab FDA label on DailyMed (effective July 23, 2026); every toripalimab label on DailyMed.
Highlights of the record
FDA label of July 23, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageLOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2
Forms and strengths
- 240 mg/6ml
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 15 through July 30, 2026
What is toripalimab used for?
From the label: indications and usageLOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) 1.1 First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). 1.2 Previously Treated Unresectable or Metastatic NPC LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. […]
FDA pharmacologic class: Programmed Death Receptor-1 Blocking Antibody.
Source: FDA drug label (LOQTORZI), Coherus Oncology, Inc., effective July 23, 2026 (SPL set 82e7921a-1e84-4988-9799-0ad7d19b2a75), via openFDA; the full label on DailyMed
What does the patient leaflet for toripalimab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about LOQTORZI?LOQTORZI is a medicine that may treat nasopharyngeal cancer by working with your immune system. LOQTORZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after treatment has ended. […] These are not all of the signs and symptoms of immune system problems that can happen with LOQTORZI. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath, swelling of ankles confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight persistent or severe muscle pain or weakness, muscle cramps low red blood cells, bruising Infusion reactions that can sometimes be severe or life-threatening. […]
Source: FDA drug label (LOQTORZI), Coherus Oncology, Inc., effective July 23, 2026 (SPL set 82e7921a-1e84-4988-9799-0ad7d19b2a75), via openFDA; the full label on DailyMed
Is there a generic for toripalimab (Loqtorzi)?
No generic toripalimab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the toripalimab label say about other medicines?
The toripalimab label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cisplatin | warnings and precautions | Immune-Mediated Pneumonitis LOQTORZI in Combination with Cisplatin and Gemcitabine LOQTORZI in combination with cisplatin and gemcitabine can cause immune-mediated pneumonitis. |
| Gemcitabine | warnings and precautions | Immune-Mediated Pneumonitis LOQTORZI in Combination with Cisplatin and Gemcitabine LOQTORZI in combination with cisplatin and gemcitabine can cause immune-mediated pneumonitis. |
| Prednisone | warnings and precautions | In general, if LOQTORZI requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. |
Source: FDA drug label (LOQTORZI), Coherus Oncology, Inc., effective July 23, 2026 (SPL set 82e7921a-1e84-4988-9799-0ad7d19b2a75), via openFDA; the full label on DailyMed
What do FAERS reports show for toripalimab?
The FDA Adverse Event Reporting System holds 15 reports that list toripalimab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 8 are coded as a death and 6 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other programmed death receptor-1 blocking antibodys
- the pharmacologic class, with prices and generics
- Toripalimab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other